Abbonarsi

Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans - 07/09/11

Doi : 10.1016/S0190-9622(99)70111-8 
Tadeusz Chorzelskia†, Takashi Hashimotoc, Barbara Maciejewskab, Masayuki Amagaid, Grant J. Anhalte, Stefania Jablonskaa
Warsaw, Poland; Fukuoke and Tokyo, Japan;and Baltimore, Maryland 
Deceased 

Abstract

Background: Cases of paraneoplastic pemphigus (PNP) have been reported associated with various lymphoproliferative malignancies and benign Castleman tumors, with the most severe course and fatal outcome seen in patients with bronchiolitis obliterans. Objective: The aim was to establish immunologic associations by coexistence of Castleman tumor, myasthenia gravis, and bronchiolitis obliterans and to evaluate the treatment modalities. Methods: Clinical studies included computed tomography of the mediastinum, computed tomography and magnetic resonance imaging of the abdominal cavity, and quantitative electromyography. Direct and indirect immunofluorescence on various substrates, immunoblot analysis, immunoprecipitation, and specific enzyme-linked immunosorbent assay using recombinant desmogleins (Dsg) were performed as immunologic assays. Results: Direct and indirect immunofluorescence including rat bladder showed intercellular antibodies. Immunoblotting disclosed antibodies to envoplakin (210 kd protein) and periplakin (190 kd protein); in addition, immunoprecipitation detected antibodies to desmoplakin I (250 kd protein). Antibodies to Dsg3 (pemphigus vulgaris antigen) were detected by specific enzyme-linked immunosorbent assay. Myasthenia gravis was controlled by drugs; however, mucocutaneous changes were not fully responsive to corticosteroids and cyclophosphamide pulses, cyclosporine, and intravenous immunoglobulins. The surgical removal of Castleman tumor did not change the course of the disease. The fatal outcome was the result of bronchiolitis obliterans that occurred after the surgery and was only transitionally controlled by plasmapheresis. Conclusion: This is the first case of paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis, and bronchiolitis obliterans. Despite a benign character of the tumor the patient died, as do all patients with bronchiolitis obliterans. Massive plasmapheresis has only a transient effect. We confirmed the presence of antibodies to Dsg 3, in addition to the set of specific paraneoplastic pemphigus antibodies against various proteins of plakin family. (J Am Acad Dermatol 1999;41:393-400.)

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 From the Department of Dermatology, Warsaw School of Medicine a; Warsaw Hospital MSWb; the Department of Dermatology, Kurume University School of Medicinec; the Department of Dermatology, Keio University School of Medicined; and the Department of Dermatology, Johns Hopkins University.5
 Reprint requests: Stefania Jablonska, MD, Department of Dermatology, Warsaw School of Medicine, Koszykowa 82a, 02-008 Warsaw, Poland.
 0190-9622/99/$8.00 + 0   16/1/98965


© 1999  American Academy of Dermatology, Inc. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 41 - N° 3

P. 393-400 - settembre 1999 Ritorno al numero
Articolo precedente Articolo precedente
  • Cutaneous laser resurfacing
  • Désirée Ratner, Yardy Tse, Nancy Marchell, Mitchel P. Goldman, Richard E. Fitzpatrick, Darrell J. Fader
| Articolo seguente Articolo seguente
  • Psoriasis causes as much disability as other major medical diseases
  • Stephen R. Rapp, Steven R. Feldman, M.Lyn Exum, Alan B. Fleischer, David M. Reboussin

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.